Surgery type | ||||
---|---|---|---|---|
Characteristic | Overall (n = 24) | Single-port (n = 7) | Multi-port (n = 17) | P-value |
Age, median (IQR), year | 61 (56–69) | 55.5 (51.3–63.5) | 61 (57–70) | 0.23 |
Race, No. (%) | > 0.99 | |||
Asian | 4 (17) | 1 (14) | 3 (18) | |
African American | 4 (17) | 1 (14) | 3 (18) | |
Hispanic | 4 (17) | 2 (29) | 2 (12) | |
Caucasian | 12 (50) | 3 (43) | 9 (53) | |
ASA, No. (%) | 0.53 | |||
II | 11 (46) | 2 (29) | 9 (53) | |
III | 11 (46) | 4 (57) | 7(41) | |
IV | 2 (8) | 1 (14) | 1 (6) | |
Age-adjusted CCI, median (IQR)a | 2 (1–3) | 2 (1–3) | 2 (2–3) | 0.79 |
Operative time, median (IQR), min | 247 (214.5–287) | 281 (223.5–290) | 237 (210–283) | 0.49 |
Biopsy Gleason score, median (IQR) | 8 (7–9) | 8 (7–8.5) | 8 (7–9) | 0.35 |
Prostate vol., median (IQR), ccb | 47 (35.3–58.4) | 38.5 (32–53.5) | 49 (36.5–58) | 0.41 |
Clinical T stage, No. (%) | 0.22 | |||
T1c | 3 (13) | 1 (14) | 2 (12) | |
T2a | 2 (8) | 0 (0) | 2 (12) | |
T2b | 3 (13) | 1 (14) | 2 (12) | |
T2c | 5 (21) | 0 (0) | 5 (29) | |
T3a | 6 (25) | 4 (57) | 2 (12) | |
T3b | 5 (21) | 1 (14) | 4 (24) | |
Clinical N stage, No. (%) | 0.28 | |||
N1 | 20 (83) | 7 (100) | 13 (76) | |
N0 | 4 (17) | 0 (0) | 4 (24) | |
Clinical M stage, No. (%) | > 0.99 | |||
M1 | 12 (50) | 3 (43) | 9 (53) | |
M0 | 12 (50) | 4 (57) | 8 (47) |